# Evaluate the Safety and Efficacy of CPX101 in Overweight and Obese Subjects Without Diabetes Mellitus

> **NCT06532578** · PHASE2 · COMPLETED · sponsor: **Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd.** · enrollment: 240 (actual)

## Conditions studied

- Overweight and Obesity

## Interventions

- **BIOLOGICAL:** CPX101 or placebo 120mg Q2W
- **BIOLOGICAL:** CPX101 or placebo 160mg Q4W
- **BIOLOGICAL:** CPX101 or placebo 160mg Q2W
- **BIOLOGICAL:** CPX101 or placebo 240mg Q4W
- **BIOLOGICAL:** CPX101 or placebo 240mg Q2W
- **BIOLOGICAL:** CPX101 or placebo 320mg Q2W
- **BIOLOGICAL:** CPX101 or placebo 360mg Q4W

## Key facts

- **NCT ID:** NCT06532578
- **Lead sponsor:** Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-08-13
- **Primary completion:** 2025-12-15
- **Final completion:** 2026-04-01
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06532578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06532578, "Evaluate the Safety and Efficacy of CPX101 in Overweight and Obese Subjects Without Diabetes Mellitus". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06532578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*